The major findings of the present study were as follows: First, statins therapy could decrease serum levels of atherogenic lipoproteins (LDL-C), TC, TG and inflammation biomarkers (hs-CRP ) from baseline to 6month and 12 month in the 2 groups of CHD patients regardless of risk stratification. The gene discussed is CRP; the disease is coronary artery disorder.